Hereditary Transthyretin Amyloidosis Global Market Report 2025 Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What External and Internal Drivers Are Contributing to the Growth of theHereditary Transthyretin Amyloidosis Market?
The hereditary transthyretin amyloidosis market’s expansion is predicted to be driven by the surge in the geriatric population. This age group, defined as individuals 65 years and older, typically necessitates specific healthcare and assistance as a result of ageing. The rise in this demographic is facilitated by improved health services and living conditions that boost life expectancy. Hereditary transthyretin amyloidosis (hATTR) prominently affects the elderly by causing escalating neuropathy and cardiomyopathy, resulting in increased illness rates among the aged. For example, the Population Reference Bureau, a non-profit organization based in the US, predicted in January 2024 that the population in the US aged 65 and older would grow from 58 million in 2022 to 82 million by 2050, showing a 47% increase. Hence, the expansion of the geriatric demographic is a major factor propelling the hereditary transthyretin amyloidosis market’s growth.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22003&type=smp
#How Will the CAGR of the Hereditary Transthyretin Amyloidosis Market Influence Its Overall Growth by 2034?
In recent times, there has been a robust growth in the market size of hereditary transthyretin amyloidosis. The market, which is projected to escalate from $1.36 billion in 2024 to $1.50 billion in 2025, will do so at a compound annual growth rate (CAGR) of 9.7%. This growth observed in the past can be credited to factors such as growing incidents of the disorder, a surge in research and development initiatives, an increasing rate of cardiac amyloidosis cases, a rise in disease awareness, and improvements in healthcare infrastructure.
The market size of hereditary transthyretin amyloidosis is predicted to witness robust expansion in the approaching years. It is projected to surge to $2.14 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 9.4%. The escalation predicted for the forecast period can be credited to several factors like the expanding elderly population, the rise of disposable incomes, a surge in hereditary transthyretin amyloidosis cases, progress in the creation of novel drugs, and an increase in genetic testing. Key trends propelling this growth during the forecast period encompass improved treatment options, progression in diagnostic skills, breakthroughs in drug development, the high demand for efficient therapies, and innovative advancements in medical technology.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22003
Which Upcoming Market Trends and Innovations Are Set to Influence theHereditary Transthyretin Amyloidosis Market’s Path Forward?
Leading businesses in the hereditary transthyretin amyloidosis market are focusing on creating groundbreaking treatments, including RNAi therapeutics, to decrease the synthesis of transthyretin (TTR) protein. RNAi therapeutics embody a category of medicine that uses RNA interference technology to deactivate specific genes, hence diminishing the synthesis of proteins that trigger diseases. As an illustration, Alnylam Pharmaceuticals, Inc., a biopharmaceutical firm based in the US, lodged a supplemental new drug application (sNDA) with the US FDA in October 2024, proposing Vutrisiran (AMVUTTRA) as a remedy for transthyretin amyloidosis with cardiomyopathy. This application highlights their cutting-edge RNAi therapeutic strategy aimed at reducing TTR protein, a critical agent in the progression of the disease. Vutrisiran’s subcutaneous method of administration offers a more manageable and patient-oriented dosage schedule compared to conventional intravenous treatments, positioning it as a possibly transformative solution for people suffering from this severe condition.
Who Are the Dominant Market Players Pushing the Boundaries of theHereditary Transthyretin Amyloidosis Market?
Major companies operating in the hereditary transthyretin amyloidosis market are Pfizer Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novo Nordisk, Regeneron Pharmaceuticals Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., BridgeBio Pharma Inc., Akcea Therapeutics, Prothena Corporation plc, Intellia Therapeutics Inc., YoITech Therapeutics, Corino Therapeutics Inc., Attralus Inc., BSIM Therapeutics SA, Eidos Therapeutics, Autotac Bio Inc.
Order Your Report Now For A Swift Delivery:
What Are the Core Segments of the Hereditary Transthyretin Amyloidosis Market, and How Do They Contribute to Growth?
The hereditary transthyretin amyloidosis market covered in this report is segmented –
1) By Type: Oral, Subcutaneous Injection, Other Types
2) By Drug Class: RNAi Agents (Patisiran), Small Interfering RNAs (siRNAs) (Vutrisiran)
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies
4) By Application: Hospital, Clinic, Other Applications
Subsegments:
1) By Oral: Tafamidis, Diflunisal, Experimental Oral Therapies
2) By Subcutaneous Injection: Patisiran, Inotersen, Vutrisiran
3) By Other Types: Intravenous Therapies, Gene Silencing Therapies, CRISPR-Based Therapies
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=22003&type=smp
What Regions Are Dominating the Hereditary Transthyretin Amyloidosis Market Growth?
North America was the largest region in the hereditary transthyretin amyloidosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary transthyretin amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Reports Similar to the Global Hereditary Transthyretin Amyloidosis Market 2025, By The Business Research Company:
Hereditary Cancer Testing Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/hereditary-cancer-testing-global-market-report
Hereditary Angioedema Therapeutics Global Market Report 2024
Hereditary Breast and Ovarian Cancer Syndrome Treatment Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
